Newsroom

DARMSTADT, Germany--(BUSINESS WIRE)--Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor...

FRANKFURT, Germany--(BUSINESS WIRE)--Green Mobility Partners (“GMP”), a Vienna-based electric locomotive leasing company, and KKR, a leading global investment firm, today announced a strategic partnership to create a leading European rail leasing platform to meet growing demand for sustainable rail infrastructure across Europe. GMP provides electric locomotives to freight and passenger rail operators across Continental Europe, supporting the sector's transition toward electrification. Founded i...

DARMSTADT, Germany--(BUSINESS WIRE)--Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor...

BOSTON--(BUSINESS WIRE)--Access Advance LLC, líder mundial en licencias de consorcios de patentes de códecs de vídeo, ha anunciado hoy que Hisense Group Holdings Co., Ltd. se ha incorporado al consorcio de patentes HEVC Advance en calidad de licenciatario. Hisense se suma a las incorporaciones recientes al consorcio de patentes de Access Advance, entre las que se destacan Xiaomi, MSI y Transsion, y amplía sus relaciones con Huawei, HP y Sharp. Hisense, con sede en Qingdao (China), es uno de los...

BOSTON--(BUSINESS WIRE)--Access Advance LLC, de wereldwijde leider in licentieverlening voor patentpools voor videocodecs, heeft vandaag aangekondigd dat Hisense Group Holdings Co., Ltd. zich bij de HEVC Advance Patent Pool heeft gevoegd als licentienemer. Hisense voegt zich bij de recente toevoegingen aan de patentpools van Access Advance, waaronder Xiaomi, MSI, Transsion, en de uitgebreide samenwerkingen met Huawei, HP en Sharp. Hisense, met hoofdkantoor in Qingdao, China, is een van 's werel...

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma...

TOKYO--(BUSINESS WIRE)--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Endometrial02 Phase 3 Trial of ENHERTU® Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer...

ROME--(BUSINESS WIRE)--Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris : ALMEX, ISIN IT0005450819) (« Mexedia » ou la « Société ») informe que le rapport de couverture analyste préparé par GBC AG – l’un des principaux cabinets indépendants de recherche financière en Allemagne –, élaboré dans le cadre d’une issuer-sponsored research, a été finalisé et est désormais publiquement disponible. Ce rapport fait suite à la reprise de la couverture analyste par GBC AG, précédemmen...

ROMA--(BUSINESS WIRE)--Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” o la “Società”) comunica che il report di analyst coverage predisposto da GBC AG – una delle principali società indipendenti di ricerca finanziaria in Germania –, sviluppato nell’ambito di un contesto di issuer-sponsored research, è stato completato ed è ora pubblicamente disponibile. Il report fa seguito alla riattivazione della copertura da parte di GBC AG, precedentemente comuni...